Clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.
Onabotulinumtoxin A successfully reduced urinary frequency and urgency, but not urgency urinary incontinence episodes.
Pharmacologic properties of oxybutynin may cause significant cognitive side effects in elderly persons.
Treatment discontinuation rate is lower than that of traditional antimuscarinics, study finds.
Only a quarter of men receiving injections of BoNT-A comply with the treatment long-term.
Prospective study reveals a 1-year surgical intervention rate of 13%.
Consistent mean reductions in urinary incontinence; durable improvements in quality of life.
Reoperation rate for transvaginal mesh prolapse surgery is 4%.
De novo OAB — defined as urgency with or without frequency and nocturia — developed in some patients.
These same patients, however, had less intense detrusor overactivity, urodynamic evaluation revealed.
Urologists and gynecologists are 49% and 30% more likely than primary care doctors to prescribe second-generation agents.
Potentially inappropriate medication use is prevalent in older adults undergoing antimuscarinic treatment for overactive bladder.
Patients' median bladder capacity improved from 150 to 200 mL and continence improved in nearly 90% of patients.
Researchers also find a significant association between smoking and secondary nocturnal enuresis.
A high cure rate was observed in women with de novo OAB symptoms following transobturator tape surgery.
Symptom improvement was greater in patients receiving tamsulosin plus darifenacin compared with tamsulosin monotherapy.
Adding vaginal estrogen may sustain the effects.
Among seniors with severe overactive bladder, a combination of solifenacin and mirabegron decreased incontinence by an average 3.5 episodes a day.
The number of neuromodulation test procedures performed per physician has increased.
Small reductions in urge incontinence episodes, voids per day with daily dose of medications.
A study found that 33.8% of women received anticholinergics compared with 19.4% of men.
OAB treatment is associated with a decreased risk of falls, study finds.
Communicating effectively about appropriate options and eliciting patient input for overactive bladder (OAB) can improve outcomes.
Regardless of delivery type, obesity ups the risk of more severe urinary symptoms, study shows.
In a study, severe nocturia predicted increased mortality risk.
Elderly patients with OAB may benefit from combined high-dosage antimuscarinics.
Repeat injections of onabotulinumtoxinA (BTXA) appear to benefit patients with non-neurogenic overactive bladder.
Improvements in efficacy and quality of life last at least six months, study finds.
Keeping abreast of the most current treatments for idiopathic OAB can lead to improved outcomes and quality of life.
Depression risk greater for men with nocturia than for women with nocturia.
Renal and Urology News Articles
- For Treating Uremic Pruritus, Evidence is Strongest for Gabapentin
- IgG-Degrading Enzyme Desensitizes, Permits HLA-Incompatible Transplant
- Evaluating Practice Options in the Shifting Health Care Landscape
- Not All High-Risk Prostate Cancers Are the Same
- Active Surveillance for Intermediate-Risk PCa May Be Unsafe
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)